NanoStilbene™

An all natural immuno-oncology adjuvant

NanoStilbene™ is prepared by low-energy emulsification which allows for better solubility, stability, and the release performance of pterostilbene nanoparticles.

The pterostilbene placed in a nanoemulsion droplet is free from air, light, and hard environment; therefore, as a delivery system, nanoemulsion can not only improve the bioavailability of pterostilbene but also protect it from oxidation and hydrolysis, while it possesses an ability of sustained release at the same time. A recommended daily dose would be 1.5 milliliters yielding 300 milligrams per dose.

In addition to the benefits of the nanoparticle pterostilbene, we chose to use medium chain triglycerides (MCT), derived from coconut oil, as one of our oil mediums in preparing the nanoemulsion. MCTs are not stored as fat, but rather convert quickly into Adenosine triphosphate (ATP), which provides energy for the body and brain at the cellular level. MCT’s are also shown to increase metabolic thermo-genesis, improve stamina, endurance, athletic performance, and energy levels, as well as exhibiting potent anti-microbial properties – providing immune system benefits and helping in balancing candida in the gut.

We, therefore, have developed an optimal oil/water (O/W) pterostilbene nanoemulsion by the PIC method on the basis of minimum surfactant concentration with increases in the solubility, stability, and the release performance of pterostilbene.

For Use under US Patent No.: 9,682,047
On June 20th, 2017, Therapeutic Solutions International, Inc. was granted U.S. Patent No.: 9,682,047 for a patent titled “Augmentation of Oncology Immunotherapies by Pterostilbene Containing Compositions”.

Example: PI3 K/Akt/NK-κB pathway and pterostilbene

Pterostilbene in multiple research papers was used against a wide group of cell lines in breast cancer and the pterostilbene was found to inhibit their growth. Yet when it was applied to breast cell lines that were not cancerous the pterostilbene did not interfere or inhibit growth.

Research has also shown that when laboratory mice were administered pterostilbene that also had cancer cells implanted in a breast cancer model the pterostilbene prevented the cells from developing into tumors. Researchers investigating the mechanism behind these effects have found that pterostilbene affects a number of signaling pathways known to be important for tumor development and metastasis. One of these pathways is the PI3 K/Akt/NK-kB signaling pathway.

The activity of this pathway in cancer cells is markedly downregulated in response to pterostilbene. This particular pathway is important for cancer cells to evade apoptosis, resist treatment, and continue to grow. Inhibition of this pathway is a target of pharmaceutical research into cancer treatments.